BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

CAPS Rating: 1 out of 5

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.


Player Avatar zzlangerhans (99.85) Submitted: 2/26/2013 5:03:03 PM : Outperform Start Price: $1.22 BCRX Score: +25.75

Three reasons to turn around and green thumb Biocryst at this level:

1. They're finally talking about a pipeline candidate with a little potential. BCX4430 broad spectrum antiviral is difficult to assess as it is still in preclinical development, but bringing BARDA into the mix will introduce a lot of volatility.

2. The stock has been beaten down pretty well and now has a market cap of 68M and 37M in cash. There is 30M in long term debt so the liquidation value of the company is still nil, but the cash position indicates that they probably won't dilute until they can manufacture some kind of positive catalyst.

3. The street doesn't want to let this stock die. Peramivir failed, development of BCX5191 was terminated, no one cares about ulodesine, the Presidio merger was canceled. But every time you think it's the last nail in the coffin, this stock bounces back. Hopefully I'll get a bit of a bounce before the lid gets nailed down for good.

Featured Broker Partners